Related references
Note: Only part of the references are listed.Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Drugs that lack single-agent activity: are they worth pursuing in combination?
Bishal Gyawali et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2017)
Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
Benjamin Carlisle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
Benjamin Carlisle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Key cost drivers of pharmaceutical clinical trials in the United States
Aylin Sertkaya et al.
CLINICAL TRIALS (2016)
Toward a Patient-Centered Value Framework in Oncology
Ethan Basch
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Unintended Consequences of Expensive Cancer Therapeutics-The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity The John Conley Lecture
Tito Fojo et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2014)
Share Paper
